NCP 01
Alternative Names: NCP-01Latest Information Update: 28 Oct 2024
At a glance
- Originator Hemostemix
- Class Antiparkinsonians; Cell therapies; Neuroprotectants
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease; Spinal cord injuries
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Spinal-cord-injuries in Canada (Parenteral)
- 19 Oct 2022 NCP 01 is still in preclinical trials for Spinal cord injuries in Canada (Hemostemix pipeline October 2022)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada (Parenteral)